Search Results 101-110 of 13137 for Tyrosine
Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...
... tyrosine kinase inhibitors [TKI\] or CRLF2- targeted concomitant medication must be documented, if used). * Conjugated bilirubin =\< 1.5 x upper limit of ...
The purpose of this study is to prospectively define the incidence of new and/or worsening hypertension in patients with B-cell malignancies on Bruton Tyrosine ...
... tyrosine kinase inhibitor therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...
... tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.